Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
LEGN 
Legend Biotech Corp (LEGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: LEGN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
22 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $74.91
1 Year Target Price $74.91
| 11 | Strong Buy |
| 10 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -4.65% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.20B USD | Price to earnings Ratio - | 1Y Target Price 74.91 |
Price to earnings Ratio - | 1Y Target Price 74.91 | ||
Volume (30-day avg) 22 | Beta 0.09 | 52 Weeks Range 25.71 - 45.30 | Updated Date 12/6/2025 |
52 Weeks Range 25.71 - 45.30 | Updated Date 12/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.28 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-12 | When - | Estimate -0.0447 | Actual -0.11 |
Profitability
Profit Margin -26.37% | Operating Margin (TTM) -15.96% |
Management Effectiveness
Return on Assets (TTM) -6.92% | Return on Equity (TTM) -22.53% |
Valuation
Trailing PE - | Forward PE 81.3 | Enterprise Value 4542782414 | Price to Sales(TTM) 5.72 |
Enterprise Value 4542782414 | Price to Sales(TTM) 5.72 | ||
Enterprise Value to Revenue 5 | Enterprise Value to EBITDA -15.34 | Shares Outstanding 184689565 | Shares Floating 364580895 |
Shares Outstanding 184689565 | Shares Floating 364580895 | ||
Percent Insiders 1.3 | Percent Institutions 46.86 |
About Legend Biotech Corp
Exchange NASDAQ | Headquaters Somerset, NJ, United States | ||
IPO Launch date 2020-06-05 | CEO & Director Dr. Ying Huang Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2900 | Website https://www.legendbiotech.com |
Full time employees 2900 | Website https://www.legendbiotech.com | ||
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. The company was founded in 2014 and is headquartered in Somerset, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.